ロード中...
Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
(1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed. However, it is still unclear whether this novel drug may improve long-term survival rates in cirrhotic patients with ascites....
保存先:
| 出版年: | J Clin Med |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7830941/ https://ncbi.nlm.nih.gov/pubmed/33466878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10020294 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|